LEXX NASDAQ Week ended 07 Aug 2026

Weekly Investor Report

Lexaria Bioscience Corp · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 5.27 USD
-10.1% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -48.9% below the Trend Line and sits at 5.6% of its 52-week range. The latest completed week returned -10.1%, after a -45.7% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal.

Setup score 14 out of 100
Latest Close 5.27 USD 7 Aug 2026
1W Return -10.1% latest completed week
4W Return -45.7% short-term follow-through
12W Return -40.7% quarterly tape
Trend Breadth 7.7% 4 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -10.1% Latest completed week; four-week move -45.7%. Indicator stack 4/31 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.96% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 51/100 23 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -48.9% below the Trend Line and sits at 5.6% of its 52-week range. The latest completed week returned -10.1%, after a -45.7% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0312-week average 0.13

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.03Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -45.7% over four weeks, -40.7% over 12 weeks, and -58.4% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-10.1%
4W-45.7%
12W-40.7%
26W-51.5%
52W-58.4%
Active trend streak0 weeks
Active weeks in one year4
Trend breadth7.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.00Latest activity-pressure read.
Pressure change-14.2%Four-week change in activity pressure.
Leadership-61.88Latest relative-leadership reading.
RS change-83.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 May 2026 Field coverage 82% Model confidence 82%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength55/100Blend of value, momentum, and quality. Underlying universe rank 46; rank 1 is best.
Value52/100Relative valuation strength. Underlying universe rank 49; rank 1 is best.
Quality49/100Profitability and accounting quality. Underlying universe rank 52; rank 1 is best.
Momentum51/100Medium-term price momentum. Underlying universe rank 50; rank 1 is best.
Growth52/100Revenue and earnings growth. Underlying universe rank 49; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
44.9x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-127.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
87.5%
Gross profit retained from each unit of revenue.
Operating margin
-3988.1%
Operating profit retained from revenue.
Free-cash-flow margin
-3757.1%
Free cash flow generated from revenue.
Return on invested capital
-429.9%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-68.5%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-74.8%
Net share repurchases relative to market value.
Shareholder yield
-74.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 23 relevant articles.

3 positive · 19 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-77.3%Distance below the 52-week high.
13-week volatility11.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+40.1%Week of 3 Apr.
Worst week-30.1%Week of 31 Jul.
Latest week-10.1%Week of 7 Aug.

Shape of recent returns

Strong gains10
Modest gains1
Flat weeks0
Modest losses4
Sharp losses11
Recent vol11.2%13-week weekly-return volatility.
Base vol15.1%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew11.2% / -11.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape16/100

Trend, activity pressure, participation, and risk combine to a 16/100 tape read.

 Indicator analysis9/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.03; No reversal markers Next-Week ExpectancyNegative 43.96%

Next-week expectancy is negative with a 43.96% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors51/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 99 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment51/100

Weighted news tone is neutral across 23 relevant articles.

Lexaria Enters a Material Transfer Agreement With PegBio Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20265.27 USD-10.1%10.31 USD24.25 USD-1.00-61.88237.6KOff
31 Jul 20265.87 USD-30.1%10.51 USD24.31 USD-0.84-56.071.5MOff
24 Jul 20268.38 USD-12.1%10.64 USD24.36 USD-0.83-37.75356.9KOff
17 Jul 20269.54 USD-1.6%10.63 USD24.39 USD-0.82-31.22445.6KOff
10 Jul 20269.70 USD15.4%10.60 USD24.41 USD-0.87-33.74395.4KOff
3 Jul 20268.40 USD5.7%10.95 USD24.42 USD-0.82-42.15150.6KOff
26 Jun 20267.95 USD-1.9%11.20 USD24.44 USD-0.73-45.43318.3KOff
19 Jun 20268.10 USD-12.1%11.48 USD24.46 USD-0.62-47.47295.0KOff
12 Jun 20269.22 USD-3.5%11.73 USD24.49 USD-0.46-39.57436.7KOff
5 Jun 20269.55 USD5.8%11.96 USD24.50 USD-0.36-36.78411.6KOff
29 May 20269.03 USD-7.4%12.16 USD24.51 USD-0.28-43.68369.2KOff
22 May 20269.75 USD9.8%12.37 USD24.52 USD-0.08-38.37479.1KOff
15 May 20268.88 USD-2.9%12.51 USD24.53 USD0.21-44.09758.3KOff
8 May 20269.15 USD-14.3%12.63 USD24.55 USD0.58-43.43820.0KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context